Antibody for detecting epithelial ovarian cancer marker and method for diagnosing epithelial ovarian cancer

US10247733B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10247733-B2
Application numberUS-201214234871-A
CountryUS
Kind codeB2
Filing dateJul 26, 2012
Priority dateJul 26, 2011
Publication dateApr 2, 2019
Grant dateApr 2, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

It is intended to find a highly specific epithelial ovarian cancer marker and to provide an antibody capable of specifically recognizing and detecting the marker or a fragment of the antibody. The present invention provides an anti-β1,6-N-acetylglucosaminyltransferase 5B antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase β1,6-N-acetylglucosaminyltransferase 5B as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for diagnosis of epithelial ovarian cancer, comprising: (a) quantitatively detecting a β-1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment present in a sample derived from a test subject using at least one anti-β-1,6-N-acetylglucosaminyltransferase 5B monoclonal antibody, or antibody fragment thereof, and (b) determining that the test subject is diagnosed to be likely to have epithelial ovarian cancer when the results of quantitatively detecting the β-1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment are greater than a predetermined cut-off value, wherein the predetermined cut-off value is the 95th percentile of the quantitative detection results of the β-1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment in the sample derived from normal individuals or patients other than epithelial ovarian cancer patients, wherein the anti-β-1,6-N-acetylglucosaminyltransferase 5B monoclonal antibody is produced by a hybridoma identified by International Accession No. FERM BP-11496, FERM BP-11497, FERM BP-11498, or FERM BP-11499. 2. The method for diagnosis of epithelial ovarian cancer of claim 1 , wherein the β-1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment comprising an epitope recognized by the anti-β-1,6-N-acetylglucosaminyltransferase 5B monoclonal antibody, or the antibody fragment thereof is the whole or a part of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1. 3. The method for diagnosis of epithelial ovarian cancer of claim 1 , wherein two anti-β-1,6-N-acetylglucosaminyltransferase 5B monoclonal antibodies are used to detect the β-1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment. 4. A method for diagnosis of epithelial ovarian cancer, comprising: (a) quantitatively detecting a β-1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment present in a sample derived from a test subject using at least one monoclonal antibody or antibody fragment thereof, and (b) determining that the test subject is diagnosed to be likely to have epithelial ovarian cancer when the results of quantitatively detecting the β-1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment are greater than a predetermined cut-off value of 4.0 ng/mL, wherein the monoclonal antibody is produced by a hybridoma identified by International Accession No. FERM BP-11496, FERM BP-11497, FERM BP-11498, or FERM BP-11499. 5. The method for diagnosis of epithelial ovarian cancer of claim 1 , wherein the sample is a body fluid, a peritoneal lavage fluid, or a tissue. 6. The method for diagnosis of epithelial ovarian cancer of claim 4 , wherein two anti-β-1,6-N-acetylglucosaminyltransferase 5B monoclonal antibodies are used to detect the β-1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment.

Assignees

Inventors

Classifications

  • of the ovaries · CPC title

  • Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

  • Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

  • against enzymes · CPC title

  • Physics · mapped topic

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10247733B2 cover?
It is intended to find a highly specific epithelial ovarian cancer marker and to provide an antibody capable of specifically recognizing and detecting the marker or a fragment of the antibody. The present invention provides an anti-β1,6-N-acetylglucosaminyltransferase 5B antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase β1,6-N-acetylgl…
Who is the assignee on this patent?
Sogabe Maki, Kubota Tomomi, Togayachi Akira, and 6 more
What technology area does this patent fall under?
Primary CPC classification G01N33/57545. Mapped technology areas include Physics.
When was this patent published?
Publication date Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).